SAFETY DATA SHEET

SECTION 1: PRODUCT IDENTIFICATION

<table>
<thead>
<tr>
<th>PRODUCT NAME</th>
<th>TESTOSTERONE CYPIONATE, USP (Micronized)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRODUCT CODE</td>
<td>0164</td>
</tr>
<tr>
<td>SUPPLIER</td>
<td>MEDISCA Inc.</td>
</tr>
<tr>
<td></td>
<td>Tel.: 1.800.932.1039</td>
</tr>
<tr>
<td></td>
<td>661 Route 3, Unit C, Plattsburgh, NY, 12901</td>
</tr>
<tr>
<td></td>
<td>3955 W. Mesa Vista Ave., Unit A-10, Las Vegas, NV, 89118</td>
</tr>
<tr>
<td></td>
<td>6641 N. Belt Line Road, Suite 130, Irving, TX, 75063</td>
</tr>
<tr>
<td></td>
<td>MEDISCA Pharmaceutique Inc.</td>
</tr>
<tr>
<td></td>
<td>Tel.: 1.800.665.6334</td>
</tr>
<tr>
<td></td>
<td>4509 Rue Dobrin, St. Laurent, QC, H4R 2L8</td>
</tr>
<tr>
<td></td>
<td>21300 Gordon Way, Unit 153/158, Richmond, BC V6W 1M2</td>
</tr>
<tr>
<td></td>
<td>MEDISCA Australia PTY LTD</td>
</tr>
<tr>
<td></td>
<td>Tel.: 1.300.786.392</td>
</tr>
<tr>
<td></td>
<td>Unit 7, Heritage Business Park</td>
</tr>
<tr>
<td></td>
<td>5-9 Ricketty Street, Mascot, NSW 2020</td>
</tr>
<tr>
<td></td>
<td>MEDISCA UK Limited</td>
</tr>
<tr>
<td></td>
<td>Tel.: 0800.029.4641</td>
</tr>
<tr>
<td></td>
<td>33 St. James's Square, London, United Kingdom SW1Y 4JS</td>
</tr>
<tr>
<td>EMERGENCY PHONE</td>
<td>CHEMTREC Day or Night Within USA and Canada: 1-800-424-9300</td>
</tr>
<tr>
<td></td>
<td>NSW Poisons Information Centre: 131 126</td>
</tr>
<tr>
<td></td>
<td>National Chemical Emergency Centre 44(0)1235239670</td>
</tr>
</tbody>
</table>

USES
Androgen; Anabolic steroid

SECTION 2: HAZARDS IDENTIFICATION

GHS CLASSIFICATION
Toxic to Reproduction (Category 1B)
Carcinogenicity (Category 1B)

PICTOGRAM

<table>
<thead>
<tr>
<th>SIGNAL WORD</th>
<th>Danger</th>
</tr>
</thead>
<tbody>
<tr>
<td>HAZARD STATEMENT(S)</td>
<td>Harmful if swallowed</td>
</tr>
<tr>
<td></td>
<td>May damage fertility or the unborn child</td>
</tr>
<tr>
<td></td>
<td>May cause cancer</td>
</tr>
<tr>
<td>ADVERSE PHYSICOCHEMICAL, HUMAN HEALTH AND ENVIRONMENTAL EFFECTS</td>
<td>Not Applicable.</td>
</tr>
<tr>
<td>PRECAUTIONARY STATEMENT(S)</td>
<td>Prevention</td>
</tr>
<tr>
<td></td>
<td>Wash thoroughly after handling</td>
</tr>
<tr>
<td></td>
<td>Do not eat, drink or smoke when using this product</td>
</tr>
<tr>
<td></td>
<td>Obtain special instructions before use</td>
</tr>
<tr>
<td></td>
<td>Do not handle until all safety precautions have been read and understood</td>
</tr>
<tr>
<td></td>
<td>Wear protective gloves, protective clothing, eye protection, face protection.</td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET

Response
IF SWALLOWED: Immediately call a poison center or medical professional; Rinse mouth.
IF EXPOSED OR CONCERNED: Get medical advice/attention.

Storage
Store locked up.

Disposal
Dispose of contents and/or container in accordance with local regulations.

HMIS CLASSIFICATION
Health Hazard 2
Flammability 1
Reactivity 0
Personal Protection G

SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

CHEMICAL NAME
Androst-4-en-3-one, 17(3-cyclopentyl-1-oxopropoxy)-(17 β)-

BOTANICAL NAME
Not applicable

SYNONYM
Testosterone cyclopentyl propionate; Testosterone cipionate; Testosterone cyclopentanepropionate

CHEMICAL FORMULA
C₂₇H₄₀O₃

CAS NUMBER
58-20-8

ALTERNATE CAS NUMBER
Not applicable

MOLECULAR WEIGHT
412.61

COMPOSITION
There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as health hazards and hence require reporting in this section.

Chemical family: Anabolic steroid; testosterone ester

NOTES

SECTION 4: FIRST-AID MEASURES

IN CASE OF EYE CONTACT
Flush with copious amounts of water for 15 minutes, separating eyelids with fingers. If irritation persists seek medical aid.

IN CASE OF SKIN CONTACT
Wash with soap & water for 15 minutes. If irritation persists seek medical aid.

IF SWALLOWED
Call a physician. Wash out mouth with water. Do not induce vomiting without medical advice.

IF INHALED
Not expected to present a significant hazard under anticipated conditions of normal use.

SYMPTOMS AND EFFECTS

SECTION 5: FIREFIGHTING MEASURES

SPECIFIC HAZARDS ARISING FROM THE CHEMICAL
Not applicable

FLAMMABLE PROPERTIES
May be combustible at high temperature

HAZARDOUS COMBUSTION PRODUCTS
Under fire conditions, hazardous fumes will be present.

SUITEABLE & UNSUITABLE EXTINGUISHING MEDIA
Small fire: dry chemical, CO2 or water spray. Large fire: dry chemical, CO2, alcohol resistant foam or water spray. Do not get water inside containers.

PROTECTIVE EQUIPMENT AND PRECAUTIONS FOR FIREFIGHTERS
Wear self-contained breathing apparatus and protective clothing to prevent contact with skin and eyes.
SECTION 6: ACCIDENTAL RELEASE MEASURES

PERSONAL PRECAUTIONS
Wear respiratory protection. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.

METHODS & MATERIAL FOR CONTAINMENT
On land, sweep or shovel into suitable containers. Minimize generation of dust.

CLEANUP PROCEDURE
Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. Wear respirator, chemical safety goggles, rubber boots and heavy rubber gloves. Stop leak if you can do it without risk. Prevent entry into waterways, sewers, basements or confined areas. Shut off all sources of ignition. Evacuate the area. If necessary, employ water fog to disperse the vapors. Absorb the matter with compatible vermiculite or other absorbing material. Place in a suitable container and retain for disposal. Ventilate and clean the affected area. Do not flush into sewerage system or to drains.

REFERENCE TO OTHER SECTIONS
See Section 7 for information on safe handling. See Section 8 for information on personal protection equipment. See Section 13 for disposal information.

SECTION 7: HANDLING AND STORAGE

PRECAUTIONS FOR SAFE HANDLING
Do not inhale. Avoid contact with eyes, skin and clothing. Avoid prolonged or repeated exposure. Wash thoroughly after handling. Store away from incompatible materials, in a well-ventilated area. Eliminate all sources of ignition. Store in accordance with local regulations. Do not store in unlabeled containers. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Use appropriate containment to avoid environmental contamination.

CONDITIONS FOR SAFE STORAGE
Store away from incompatible materials, in a well-ventilated area. Eliminate all sources of ignition. Store in accordance with local regulations. Do not store in unlabeled containers. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Use appropriate containment to avoid environmental contamination.

STORAGE CONDITIONS
Store in original container, tightly sealed, protected from direct sunlight and moisture. Preserve in well-closed, light-resistant containers.

SPECIFIC END USE(S)
See Section 1

SECTION 8: EXPOSURE CONTROLS/ PERSONAL PROTECTION

<table>
<thead>
<tr>
<th>Chemical Name: TESTOSTERONE CYPIONATE</th>
<th>CAS #: 58-20-8</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>TWA</td>
</tr>
<tr>
<td>OSHA PEL</td>
<td>N/L</td>
</tr>
<tr>
<td>ACGIH TLV</td>
<td>N/L</td>
</tr>
<tr>
<td>NIOSH</td>
<td>N/L</td>
</tr>
<tr>
<td>AIHA WEEL</td>
<td>N/L</td>
</tr>
<tr>
<td>Safe Work Australia HSIS</td>
<td>N/L</td>
</tr>
<tr>
<td>HSE</td>
<td>N/L</td>
</tr>
<tr>
<td>GESTIS</td>
<td>N/L</td>
</tr>
</tbody>
</table>

N/L = Not Listed

EXPOSURE GUIDELINES
Consult local authorities for provincial or state exposure limits. Particulates not otherwise regulated, respirable fraction: 5 mg/m³
SAFETY DATA SHEET

PERSONAL PROTECTIVE EQUIPMENT

**Eyes:** Wear appropriate protective eyeglasses or chemical safety goggles as described by WHMIS or OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166. **Skin:** Wear appropriate gloves to prevent skin exposure. **Clothing:** Wear appropriate protective clothing to minimize contact with skin. **Respirators:** Follow WHMIS or OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced. **Thermal Hazards:** For products representing a thermal hazard, appropriate Personal Protective Equipment should be used.

SPECIFIC ENGINEERING CONTROLS

Adequate mechanical ventilation. Fumehood, eye wash station, and safety shower.

NOTES

USP: ELV: industrial TWA: 4 micrograms/m³

### SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>PROPERTY</th>
<th>VALUE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Physical State</strong></td>
<td>Solid</td>
</tr>
<tr>
<td><strong>Description</strong></td>
<td>White or creamy white crystalline powder. Is odorless or has a slight odor, and is stable in air.</td>
</tr>
<tr>
<td><strong>Solubility</strong></td>
<td>Insoluble in water; freely soluble in alcohol, in chloroform, in dioxane, and in ether; soluble in vegetable oils.</td>
</tr>
<tr>
<td><strong>Odor</strong></td>
<td>Odorless or slight odor</td>
</tr>
<tr>
<td><strong>Flammability</strong></td>
<td>May be combustible at high temperature</td>
</tr>
</tbody>
</table>

#### AUTO-IGNITION TEMPERATURE

- Not available

#### BOILING POINT

- Not available

#### DECOMPOSITION TEMPERATURE

- Not available

#### EVAPORATION RATE

- Not available

#### EXPLOSIVE LIMIT

- Not available

#### FLASH POINT

- >93.3 °C, >199.94 °F (Closed cup)

#### log P (OCTANOL-WATER)

- Not available

#### LOWER FLAMMABLE/EXPLOSIVE LIMIT(S)

- Not available

#### MELTING/FREEZING POINT

- (101 - 102)°C, (213.8-215.6)°F

#### OXIDIZING PROPERTY

- Not available

#### ODOR THRESHOLD

- Not available

#### pH

- Not available

#### RELATIVE DENSITY (WATER = 1)

- Not available

#### SPECIFIC GRAVITY

- Not available

#### UPPER FLAMMABLE/EXPLOSIVE LIMIT(S)

- Not available

#### VAPOR PRESSURE

- < 0.0000001 kPa (25°C)

#### VAPOR DENSITY (AIR = 1)

- Not available

#### VISCOSITY

- Not available

The physical data presented above are typical values and should not be construed as a specification.

### SECTION 10: STABILITY AND REACTIVITY

<table>
<thead>
<tr>
<th>PROPERTY</th>
<th>VALUE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Reactivity</strong></td>
<td>Not established</td>
</tr>
<tr>
<td><strong>Chemical Stability</strong></td>
<td>Stable under recommended storage conditions</td>
</tr>
<tr>
<td><strong>Incompatible Materials</strong></td>
<td>Strong oxidants</td>
</tr>
<tr>
<td><strong>Hazardous Decomposition Products</strong></td>
<td>Toxic fumes of carbon monoxide, carbon dioxide and other gases may occur</td>
</tr>
<tr>
<td><strong>Hazardous Polymerization</strong></td>
<td>Will not occur</td>
</tr>
</tbody>
</table>

Last Revision: 08/2019
POSSIBILITY OF HAZARDOUS REACTION

Not established

CONDITIONS TO AVOID

Moisture, sunlight and extreme temperatures

SECTION 11: TOXICOLOGICAL INFORMATION

ACUTE TOXICITY

Oral: Rat: LD50: (mg/kg): Not available
Dermal: Rabbit LD50: (mg/kg): Not available
Inhalation: Rat: LC50: (mg/L/4hr): Not available

SKIN CORROSION/IRRITATION

Due to lack of data the classification is not possible.

SERIOUS EYE DAMAGE/EYE IRRITATION

Due to lack of data the classification is not possible.

RESPIRATORY SENSITIZATION

Due to lack of data the classification is not possible.

SKIN SENSITIZATION

Due to lack of data the classification is not possible. Suspected skin sensitizer: The Toolbox profiler Protein binding alerts for skin sensitization by OASIS v1.3 gives an alert for skin sensitisation

GERM CELL MUTAGENICITY

Due to lack of data the classification is not possible.

CARCINOGENICITY

OSHA TESTOSTERONE CYPIONATE is listed.
NTP TESTOSTERONE CYPIONATE is not listed.
IARC TESTOSTERONE CYPIONATE is listed in group 2a (probably carcinogenic to humans).
California Proposition 65 This product contains the following chemical known to the State of California to cause cancer and birth defects or other reproductive harm: TESTOSTERONE CYPIONATE.

ADDITIONAL CARCINOGENICITY INFORMATION

Probably carcinogenic to humans.

In humans receiving long-term therapy with high doses of androgens, there were rare cases of hepatocellular carcinomas. Studies in mice given subcutaneous implants of testosterone showed an increase in cervical-uterine tumors. This effect was not seen in mice and rats given subcutaneous injections of testosterone or in rats given subcutaneous implants. Testosterone is also known to increase the number of tumors and decrease the degree of differentiation of chemically induced carcinomas of the liver in rats.

May cause cancer.

Hepatocellular carcinomas and hepatic neoplasms have been associated rarely with long-term, high-dose anabolic steroid therapy.

Suspected carcinogen: The Toolbox profiler Carcinogenicity (genotox and nongenotox) alerts by ISS gives an alert for carcinogenicity; ISS Carcinogenicity model in VEGA (Q)SAR platform predicts that the chemical is Carcinogen (moderate reliability)

REPRODUCTIVE TOXICITY

May damage fertility or the unborn child. Studies in humans have shown that androgens administered during pregnancy cause masculinization of the external genitalia of the female fetus; the degree of masculinization is dose related. In males, absent, low, or reduced sperm or sperm function resulting in possible infertility may occur during high-dose therapy with androgens. In females treated with androgens, the absence of menstruation may result, impairing fertility. Premature bone maturation and decreased birthweight have been reported with the use of anabolic steroids in humans.

Suspected toxic for reproduction: CAESAR developmental toxicity model in VEGA (Q)SAR platform predicts that the chemical is Toxicant (good reliability)

SPECIFIC TARGET ORGAN TOXICITY - SINGLE EXPOSURE

Liver and endocrine system

SPECIFIC TARGET ORGAN TOXICITY - REPEATED EXPOSURE

Due to lack of data the classification is not possible.

ASPIRATION HAZARDS

Based on available data, the classification criteria are not met.
SIGNS AND SYMPTOMS OF EXPOSURE
Pharmacologically active material. Occupational exposure may cause physiological effects.

Symptoms related to the physical, chemical, and toxicological characteristics:

Delayed and immediate effects of exposure:

Cross sensitivity:
Persons sensitive to one anabolic steroid or androgen may be sensitive to this material also.

Medical conditions aggravated by exposure:

POTENTIAL HEALTH EFFECTS
Inhalation
May be harmful if inhaled. May cause respiratory tract irritation.

Ingestion
May be harmful if swallowed.

Skin
May be harmful if absorbed through skin. May cause skin irritation

Eyes
May cause eye irritation.

SECTION 12: ECOLOGICAL INFORMATION

TOXICITY
EC50: 48 Hr: Crustacea: (mg/L): Not available
LC50: 96 Hr: Fish: (mg/L): 2.05*
EC50: 72 or 96 Hr: Algae (or other aqua plants): (mg/L): Not available

PERSISTENCE AND DEGRADABILITY
Suspected persistent in the environment: Ready biodegradability model (IRFMN) in VEGA (Q)SAR platform predicts that the chemical is NON Readily Biodegradable (moderate reliability); The Danish QSAR database contains information indicating that the substance is predicted as non readily biodegradable

BIOACCUMULATIVE POTENTIAL
Not available

MOBILITY IN SOIL
Insoluble in water

OTHER ADVERSE EFFECTS
Not available

This product is not intended to be released into the environment

NOTES
*Toxicity model (KNN/Read-Across) in VEGA (Q)SAR platform prediction (good reliability)

SECTION 13: DISPOSAL CONSIDERATIONS

WASTE DISPOSAL
Dispose of in accordance with federal / local laws and regulations. Avoid release into the environment.

SECTION 14: TRANSPORT INFORMATION

UN PROPER SHIPPING NAME
Not dangerous good

UN NUMBER
Not applicable

CLASS
Not applicable

PACKING GROUP
Not applicable
**SAFETY DATA SHEET**

**AUSTRALIA**

**HAZCHEM**
Not Applicable

**EU**
**TRANSPORT IN BULK ACCORDING TO ANNEX II OF MARPOL 73/78 AND THE IBC CODE**
Not listed

**ENVIRONMENTAL HAZARDS**
Not available

**SPECIAL SHIPPING INFORMATION**
Not applicable

## SECTION 15: REGULATORY INFORMATION

### UNITED STATES REGULATIONS

<table>
<thead>
<tr>
<th>Chemical Name &amp; CAS</th>
<th>CERCLA 40 CFR Part 302.4</th>
<th>SARA (Title III) 40 CFR Part 372.65</th>
<th>EPA 40 CFR Part 355 Appendix A</th>
<th>Appendix B</th>
<th>Pennsylvania</th>
<th>Right-to-know New Jersey</th>
<th>Massachusetts</th>
<th>California Prop 65</th>
</tr>
</thead>
<tbody>
<tr>
<td>TESTOSTERONE CYCIONATE, 58-20-8</td>
<td>N/L</td>
<td>N/L</td>
<td>N/L</td>
<td>N/L</td>
<td>X</td>
<td>N/L</td>
<td>X*</td>
<td>X</td>
</tr>
</tbody>
</table>

N/L = Not Listed; X = Listed

### AUSTRALIAN REGULATIONS

<table>
<thead>
<tr>
<th>Chemical Name &amp; CAS</th>
<th>Poisons and Therapeutic Goods Regulation</th>
<th>Therapeutic Goods Act</th>
<th>Code of Practices - Illicit Drug Precursors</th>
</tr>
</thead>
<tbody>
<tr>
<td>TESTOSTERONE CYCIONATE, 58-20-8</td>
<td>Listed*</td>
<td>Listed as Schedule 4*</td>
<td>N/L</td>
</tr>
</tbody>
</table>

N/L = Not Listed

### EU REGULATIONS

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>TESTOSTERONE CYCIONATE, 58-20-8</td>
<td>N/L</td>
<td>N/L</td>
<td>N/L</td>
<td>N/L</td>
<td>N/L</td>
<td>N/L</td>
<td>N/L</td>
</tr>
</tbody>
</table>

N/L = Not Listed; X = Listed

Any EU regulation not listed above is not applicable to this product.

**NOTES**
*Listed as the base

## SECTION 16: OTHER INFORMATION

**REFERENCES**
Available upon request
SAFETY DATA SHEET

ABBREVIATIONS AND ACRONYMS


LAST REVISION

08/2019

SUPERSEDES

04/2019

For a list of changes to the SDS since the last version, please communicate with MEDISCA at www.medisca.com

DISCLAIMER

This document was created in accordance with OSHA, Safe Work Australia and WHMIS regulations. The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product. MEDISCA® shall not be held liable for any damage resulting from handling or from contact with the above product. Recipients of the product must take responsibility for observing existing laws and regulations.

SUPPLEMENTARY INFORMATION

For all country specific requirements not outlined on this Safety Data Sheet, please request Supplementary Page to this Safety Data Sheet.